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EXECUTIVE SUMMARY
While there has been remarkable global progress in the prevention of mother-to-child HIV 
transmission (PMTCT), efforts to scale up antiretroviral therapy (ART) and achieve the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) “90–90–90” targets (90% diagnosed, 90% of those 
infected on ART, 90% on ART viral suppressed) have been less robust in children than in adults 
living with HIV. These discrepancies reflect substantial gaps in essential services and numerous 
missed opportunities to engage children in care and provide effective treatment. Although not 
new, family-centered care models that provide HIV services comprehensively to families as a 
unit, rather than providing separate services to children and adults, have the potential to address 
family needs and break down social, physical, and emotional barriers to accessing care. The 
family-centered care study (FAM-CARE) aims to contribute to our understanding of the role of 
family-centered care models (FCCM) in improving pediatric HIV outcomes in a sub-Saharan 
African setting. 
Methodology
The FCCM program is a model where a child or adolescent (0–<19 years old) living with HIV 
is provided HIV care and treatment services with at least one family member involved in the 
support for the child. Family members include children and adults, HIV-negative and HIV-positive. 
For family members who have unknown HIV status, HIV counseling and testing and follow up 
services are provided. Participants attend clinic visits together as a family unit to receive HIV care, 
including laboratory and pharmacy services. Participants see the same provider at each visit, 
medications for family members could be collected by one family member, and a comprehensive 
filing system allowed all clinical records for each family to be stored in one folder. Clinic visits are 
scheduled for a minimum of four visits per year; all medical records are to be pulled for all family 
members ahead of the visit and FCCM participants prioritized in receiving services at the facility. 
The FAM-CARE study enrolled a prospective cohort of children living with HIV (age <15 years) 
and their caregivers (HIV-positive or HIV-negative) and other family members living with HIV to 
evaluate the effects of a FCCM. Four facility clusters (two hospitals and two health facilities, and 
their filter clinics) in the Hhohho region of Eswatini were randomized to either implement the 
FCCM intervention, where all family members living with HIV are seen together as a unit and 
receive their care together, or to the control standard of care group, where adults and children 
are seen in separate clinics. The cohort of 379 children living with HIV was followed in both 
arms for a minimum of 12 months after enrollment. The primary objective was to evaluate the 
effect of the FCCM program on the rates of viral suppression and retention in care, comparing 
children enrolled in FCCM versus control sites. The study also evaluated factors associated with 
viral suppression and retention. Caregiver interviews and medical chart abstraction were used 
to collect data on demographic characteristics, HIV and ART history, interim HIV history, viral 
load, CD4 count, medical visit attendance, and drug pick-ups for children living with HIV and 
any caregivers or family members living with HIV. For children, viral load was obtained as part 
of the study at enrollment, 6, and 12 months (and 18 months for those followed through that 
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time), with laboratory assays conducted at a central laboratory. Qualitative in-depth interviews 
with caregivers and health workers at the intervention sites were used to assess feasibility and 
acceptability of the FCCM model. 
KEY FINDINGS
Quantitative findings
A cohort of 379 children living with HIV and their caregivers from 363 unique families, including 
363 caregivers (97% living with HIV themselves) and 28 other family members living with HIV 
(children, adolescents, and adults), were enrolled and followed for a minimum of 12 months; 
87 percent had follow-up through 12 months and 57 percent through 18 months. Other family 
members included children, adolescents, and adults living with HIV, living in the same household 
as the child living with HIV enrolled in the FAM-CARE study.
Treatment regimen at enrollment 
At enrollment, 43 percent of children were receiving nevirapine-based ART regimens. These 
nevirapine-based regimens are considered suboptimal and were associated with lower levels 
of viral suppression. These findings directed attention to the critical need to review pediatric 
treatment regimens and optimize ART regimens for all children as they grow and as more potent 
and less toxic regimens become available. These findings were published in 2019 in the Pediatric 
Infectious Diseases Journal. 
Viral suppression and undetectable viremia
Viral suppression (HIV RNA <1,000 copies/mL) improved in both study arms from 78 percent 
at enrollment to 90 percent at 12 months and 87 percent for those followed to 18 months. 
Children with undetectable viral load (HIV RNA <400 copies/mL) improved from 74 percent at 
enrollment to 87 percent at 12 months and 84 percent for those followed to 18 months. Overall, 
among children who had viral suppression at enrollment, 97 percent remained suppressed at 
12 months follow up; 62 percent of children who were unsuppressed at enrollment achieved 
viral suppression at 12 months follow up. There were no statistically significant differences in 
the intervention versus control groups in viral suppression or undetectable viral load at 12 or 18 
months follow-up. 
Factors associated with viral suppression and undetectable viremia
In unadjusted bivariate analyses among all children at 12 months after enrollment, several 
factors were associated with viral suppression (HIV RNA <1,000 copies/mL). Children who were 
not aware of their HIV status tended to be less likely than children who were aware of their HIV 
status to be virally suppressed (OR:0.46; 95% CI:0.20, 1.08, p=0.068). Compared to children with 
caregivers under age 25 years, children with older caregivers aged 30–40 years (OR: 5.53; 95% 
CI: 1.80, 17.00) and aged >40 years (OR: 3.93; 95% CI:1.30, 11.85) were significantly more likely 
to be suppressed. The odds of suppression among children with HIV-negative caregivers were 
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significantly lower than the odds of suppression among children with HIV-positive caregivers (OR: 
0.15; 95% CI: 0.05, 0.49). At study entry, children on nevirapine (NVP)-based ART had significantly 
lower levels of viral suppression (73%) than those on efavirenz (EFV) (87%) or lopinavir-ritonavir 
(LPV/r)-based (79%) ART (p=0.042). At 12 months, while rates of viral suppression remained 
lowest in those on NVP-based ART (87%) compared to EFV-based (94%) and LPV/r-based (91%) 
ART, this was not statistically significant (p=0.31). Study intervention versus control group was 
not significantly associated with viral suppression at 12 (p=0.48) or 18 months (p=0.08) after 
enrollment.
In unadjusted bivariate analyses among all children at 12 months after enrollment, similar factors 
were associated with undetectable viremia (HIV RNA <400 copies/mL). The odds of undetectable 
viremia tended to be lower among children who did not know their HIV status compared to 
children who knew their HIV status (OR: 0.55; 95% CI: 0.26, 1.14, p=0.10). Children in the care 
of caregivers aged 30–40 years (OR: 5.24; 95% CI: 1,83, 15.04) and aged >40 years (OR:3.15; 
95% CI: 1.14, 8.68) were significantly more likely to have undetectable viremia than children 
with younger aged caregivers (<25 years). Children in the care of HIV-negative caregivers versus 
caregivers living with HIV were less likely to have undetectable viremia (OR:0.15; 95% CI: 0.05, 
0.46). Although rates of undetectable viremia at 12 months after enrollment were lowest in those 
on NVP-based ART (84%) compared to EFV-based (90%) and LPV/r-based (89%) ART, this was 
not statistically significant (p=0.38). Study intervention versus control group was not significantly 
associated with undetectable viremia at 12 (p=0.63) or 18 months (p=0.38) after enrollment.
There was a non-significant trend toward higher odds of viral suppression and undetectable 
viremia among older versus younger children. Overall, 94 percent of children aged 10–14 years 
had viral suppression at 12 months follow-up compared with 90 percent of children aged 5–9 
years and 85 percent of children aged <5 years. Similarly, undetectable viral load was observed in 
91 percent of children 10-14 years, 87 percent of those aged 5–9 years, and 81 percent of those 
aged <5 years. There was not a significant difference in the levels of suppression or detectability 
by intervention versus control groups when stratified by age.
Retention, adherence, treatment interruption, and HIV disclosure
There were no significant differences between intervention and control groups in retention in 
care, interruption of ART, reported adherence, or disclosure at 12 months (Table 5). At 12 months 
follow-up, 93 percent of children expected to be seen at the 12-month visit had a documented 
clinic visit, with no significant difference between groups (91% intervention, 94% control, 
p=0.53). At the 12-month visit, ART interruption was reported by 16 percent in the intervention 
and 15 percent in the control groups (p=0.82); good adherence was reported by 84 percent in 
the intervention and 87 percent of the control groups (p=0.32); and last two drug pick-ups were 
reported to be on time for 88 percent of intervention and 92 percent of control group children 
(p=0.18). The proportion of children who did not know their HIV status at enrollment but learned 
of their HIV status during the study was low and not statistically different between groups (6% 
intervention and 5% control, p=0.69). In the more limited sample of 216 children with 18-month 
follow-up, 12 percent reported ART interruption, 93 percent reported good ART adherence, and 
87% percent reported the last two drug pick-ups were on time, with no significant differences 
between groups.
4  ■  Piloting and evaluating family-centered care in Eswatini
Qualitative findings
Benefits of FCCM
Caregivers liked the FCCM model because they felt it encouraged family members to disclose 
their HIV status to other family members and support each other in taking antiretroviral (ARV) 
drug regimens. Caregivers reported that they thought FCCM encouraged men to take a proactive 
support role for both women and children in HIV care and treatment, and reduced HIV-related 
stigma within the family. Caregivers viewed the counseling as better in the FCCM program than it 
was in the standard of care.
Health workers said FCCM program allowed them to track family histories, identify family 
challenges to HIV care and treatment, and identify long lasting solutions to problems. Overall, 
health workers perceived improved ART adherence, retention, and health status of children in the 
FCCM program. 
Challenges in FCCM
Caregivers felt they had to incur additional costs for clinic visits for multiple family members, as 
the FCCM program required the family to visit the clinic together. There were schedule conflicts 
with school-aged children attending school and conflicts for older children who also attended 
weekend teen-support groups, as FCCM required additional family visits. 
Within some facilities, health workers said that not all families attended clinic visits together 
as a family unit. Some families rotated family members to pick up ARV drug refills for the whole 
family. Health workers also had challenges with managing a large group of family members at the 
same time and noted staff shortages. Both caregivers and health workers mentioned difficulty in 
discussing sensitive health information in the presence of other family members.
CONCLUSION AND RECOMMENDATIONS
High levels of viral suppression and ART adherence (90% and 85% overall, respectively) as well 
as retention were observed in both arms of the FAM-CARE study, which made it difficult to detect 
differences between children in control and intervention arms. Younger caregivers were less likely 
to have a child with viral suppression, and viral suppression was lower among children aged <5 
years compared to older children. 
The standard of care in Eswatini during the study period included viral load monitoring every 
12 months for stable children less than 10 years old and every 6 months for children aged 10 
to 19 years, and availability of teen support groups. Both intervention and control sites were to 
receive routine viral load testing every six months (although this was not always followed in the 
control sites) and the availability of teen support groups. In the control sites, it is possible that the 
additional attention of being enrolled in a study, with the caregiver interviewed at each study visit, 
resulted in improved viral suppression in this group, which limited the ability to detect a difference 
between control and intervention group participants. 
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The FCCM program was well-liked by both caregivers and health care workers overall. Both 
caregivers and health workers viewed FCCM as encouraging HIV disclosure among family 
members and supporting each other in ART adherence, although analysis of FAM-CARE study 
data did not find differences in new HIV status disclosures to children or in ART adherence 
between study groups. Challenges discussed by both caregivers and health workers included 
clinic visit scheduling conflicts with school and teen support groups, making it difficult to 
implement FCCM as planned, as well as difficulties in discussing sensitive health information in 
the presence of other family members. 
These results reflect the significant challenges for families with school-aged children in attending 
clinic visits together as a family as FCCM intended. For older children, teen support groups may 
be sufficient for ensuring positive outcomes in viral suppression and undetectable viremia. A 
higher proportion of older children achieved viral suppression and undetectable viremia (94% and 
91%, respectively, for those aged 10–14 years) in both arms at 12 months after enrollment than 
the younger children (85% and 82% respectively, for those aged <5 years). 
Factors associated with viral suppression highlight important areas for enhancement in pediatric 
HIV care. Additional support (e.g., for keeping appointments, retention, understanding the need to 
take medication as prescribed, adherece) for adolescent or young adult caregivers, HIV-negative 
caregivers, caregivers of children under age 5 years, and for all caregivers in disclosing the child’s 
HIV status could improve pediatric HIV outcomes. 
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INTRODUCTION
Over the past two decades there has been much progress in prevention of mother-to-child HIV 
transmission in efforts to scale up antiretroviral therapy (ART) and achieve the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) “90–90–90” targets (90% diagnosis, 90% of those 
infected-on ART, 90% on ART with viral suppression). Achievement toward these goals has been 
less robust for children compared with adults (WHO 2014; UNAIDS 2014). These discrepancies 
reflect substantial gaps in essential services and numerous missed opportunities to engage 
children in care and provide effective ART.
With the 2016 WHO recommendations for universal treatment of all individuals living with HIV 
regardless of clinical or immune status, parents and children living with HIV will require ART 
(WHO 2016). The family forms the basic source of care and support for children in sub-Saharan 
Africa, and children’s health and well-being are dependent on the physical, emotional, and 
social health of their parents and caregivers; a major aim of ART is to keep the family unit alive 
and well, benefitting caregivers and parents and also improving the well-being of their children 
(Leeper et al. 2010). Most HIV services are delivered with a focus on individual care, with little 
or less attention to their family or social context. Provision of ART has generally been separated 
for adults and children because of different areas of expertise and because prior treatment 
guidelines were dependent on CD4 and WHO clinical stage for ART eligibility, and children and 
their parents may have qualified for treatment months or years apart. However, comprehensive 
pediatric HIV prevention, treatment, and support will likely not be achieved if the child is taken 
out of the context of the family. Family-centered care models (FCCM) have emerged as an 
approach to comprehensively care for the needs of all HIV-positive family members, particularly 
the mother and child (Ritcher et al. 2010). Approaches that engage the family as a whole may 
offer advantages in improving retention in care and adherence with ART over the long run, and 
breaking barriers related to male partner involvement and disclosure processes (Rochat et al. 
2011; Beatancourt et al. 2010). 
While these models are not new, there are limited data to provide insights on the role of 
FCCM on pediatric and adult HIV outcomes. A 7-year retrospective analysis of data following 
implementation of an integrated family-focused approach to pediatric HIV care in 10 health 
facilities and 10 community clinics in Uganda reported a 50-fold increase in family units 
registered in health care (from 70 to 3,653), a 43-fold increase in children actively enrolled in 
care (from 86 to 3,726) and a 23-fold increase in children receiving ART (from 86 to 2,015) 
(Luyirika et al. 2013). In a study that examined the association between co-enrollment of family 
members living with HIV into care and outcomes of women initiating ART for PMTCT in 12 HIV care 
and treatment programs in eight sub-Saharan African countries, the risk of loss to follow-up was 
significantly greater among women living with HIV who did not have a family member living with 
HIV co-enrolled in care compared to those with a family member enrolled (19% vs 3–8% after 36 
months on ART, respectively) (Myer et al. 2014). These limited data suggest that a family-focused 
care approach may lead to improved retention, ART adherence, and viral suppression for both 
children and adults. However, implementation of such a program has also been found to have 
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challenges, including issues of disclosure to partners and difficulties in engaging male partners 
(Towne-Gold et al. 2009; Hosegood et al. 2010).
Additionally, achieving the third “90” (90% viral suppression) is particularly challenging in children 
as most programs do not include pediatric viral load monitoring as part of routine care. The 
use of 2010/2013 WHO immunologic criteria to define treatment failure results in significant 
misclassification: in a study in Western Kenya, 6 percent (2 of 34) of children classified as 
treatment failure actually had undetectable viral load, and 65 percent (45 of 69) of children 
thought to have treatment success had detectable viral load, supporting WHO recommendations 
for routine viral load monitoring (Dufort et al. 2016). The potential use of viral load monitoring as 
a tool to promote adherence has had some evaluation among adults, but not among children. A 
meta-analysis of eight studies in eight countries found a trend for re-suppression following viral 
load testing with targeted adherence support for adults living with HIV found to have detectable 
viremia (Bonner et al. 2013). Studies are critically needed to determine how to optimally 
implement and use virologic testing among children living with HIV (Roberts et al. 2016).
In a recent large cross-sectional survey in Malawi and a 2013 systematic review of viral 
suppression in adults living with HIV on ART, viral suppression to HIV RNA <1,000 copies/mL 
ranged from 62 to 71 percent (intention-to-treat analysis) (McMahon et al. 2013; Maman et al. 
2016). Data on virologic outcomes for children on ART in sub-Saharan Africa are more limited. In 
a cross-sectional survey of viral suppression (HIV RNA <80 copies/mL) among children on first-
line ART for >6 months in 10 nurse-led clinics in Lesotho, viral suppression was found in only 
72 percent of 191 children; no predictors for viral outcome were identified (Puga et al. 2016). 
Similarly, in a study of 742 children living with HIV initiating first-line ART in South Africa between 
2008 and 2011, only 62 percent achieved a viral load <50 copies/mL six months after ART 
initiation (Pillay et al. 2015). In a descriptive study using data from a pilot program in 2012–2013 
of routine viral load monitoring in 12,063 individuals living with HIV (including 580 children <10 
years and 588 adolescents 10–19 years) in Shiselweni, Eswatini, 16 percent were found to have 
detectable viral load (HIV RNA ≥100 copies/mL); children had a 2.6-fold and adolescents a 3.2-
fold increased odds of having a detectable viral load (29% of children <10 years and 35% of 
adolescents 10–19 years had detectable viremia) and were less likely to re-suppress at re-testing 
after adherence counseling (Jobanputra et al. 2015). Thus, the available pediatric data suggest 
viral suppression below the level of assay quantification (HIV RNA <50–400 copies/mL) is 
observed in 62 to 78 percent of children after >6–24 months of ART. In a pooled analysis of data 
from 5,485 children living with HIV who initiated ART at seven South African treatment programs 
with viral load monitoring, the probability of having a single viral load measurement >1,000 
copies/mL was 17 percent at one year (95% CI 15.8–18.1) and 32 percent (95% CI 30.2–34.1) 
at 3 years after starting ART; the frequency of ART failure (two viral load >1,000 copies/mL) was 
19 percent by 36 months (Davies et al. 2011). There are many factors that contribute to poor 
overall virologic response to ART and problems with retention and ART adherence in children, 
many of which stem from the fact that children are dependent upon adults for administration of 
their medications and attendance at clinic appointments. A family-focused program of care may 
serve to improve both pediatric retention in care and viral suppression. 
In 2017, EGPAF-Eswatini initiated a pilot family-centered service delivery program in selected 
health facilities in the Hhohho region to provide more efficient and effective services to promote 
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better ART initiation and retention in care for adults and children. The roll-out of these services 
provided a platform for introducing and evaluating routine HIV viral load testing and monitoring in 
children. Two of four health care clinic clusters in the region were randomized to provide the new 
FCCM, allowing a comparison of pediatric retention and viral load suppression between FCCM 
program and control facilities in which care for adults and children are provided separately. Data 
for the family care (FAM-CARE) study were collected during September 2017 and July 2019.
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METHODOLOGY
OBJECTIVES
The overall aim of this study was to demonstrate whether a family-centered care approach to HIV 
care through FCCM improved rates of viral suppression and retention of children living with HIV in 
care. The specific objectives of the FAM-CARE study were:
Primary objectives
1. Evaluate the effect of the FCCM program of HIV care on the proportion of children living with 
HIV on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay 
detection) 18 months after enrollment.
2. Evaluate the effect of a FAM-CARE program of HIV care on the proportion of children living 
with HIV on ART with HIV RNA ≥1,000 copies/mL 18 months after enrollment into the study.
Secondary objectives
1. Evaluate the effect of a FAM-CARE program of HIV care on the proportion of children with viral 
suppression (undetectable HIV RNA levels) and with HIV RNA ≥1,000 copies/mL at 6 and 12 
months after enrollment into the study.
2. Determine the individual and family factors associated with viral suppression and 
undetectable viremia in children 12 months after enrollment in FCCM and control facilities.
3. Evaluate the effect of a FAM-CARE program of HIV care on loss to follow-up (not seen in 
clinical care >3 months) and ART initiation in HIV-positive children not on ART at study entry.
4. Evaluate the acceptability of the FCCM program to caregivers and health care providers.
STUDY DESIGN
The FAM-CARE study was a two arm, prospective cohort study of HIV-positive children from 
selected facility sites implementing the FCCM program and control sites using the standard of 
care (separate adult and pediatric HIV care clinics) to assess the effects of the FCCM program 
on retention and viral suppression in HIV-positive children on ART. Program health care facility 
clusters were randomized to initiate the pilot FCCM program (two health care facility clusters) or 
continue to provide the current standard of HIV care with separate pediatric and adult HIV clinics 
(two health care facility clusters). The FAM-CARE study evaluated the effect of the program on 
pediatric viral suppression and retention in care using both quantitative and qualitative methods. 
Quantitative data collection included interviews conducted with caregivers to gather demographic, 
medical history, family history, HIV, and treatment history for caregivers, children, and other family 
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members; medical chart abstraction to gather information on visit attendance, HIV treatment, 
pharmacy pick-up, and CD4 and viral load history if on ART for caregivers, children, and other 
family members; and collection of dried blood spot (DBS) specimens from children to test for viral 
load every six months. Data collection was conducted at enrollment and at every three months 
for children and caregivers, and every 6 months for other family members, for a minimum of 12 
months after enrolment. Qualitative one-on-one in-depth interviews (IDIs) were conducted with 
randomly selected caregivers and with purposively selected health workers (HWs) at the FCCM 
sites to assess feasibility and acceptability of the FCCM program.
Study setting and study population
The FAM-CARE study sites were selected from PEPFAR-supported health facilities in Hhohho 
region, which consist of four clinic clusters consisting of a “parent” hospital or health center 
(Mbabane Government Hospital, Pigg’s Peak Government Hospital, Emkhuzweni Health Centre, 
and Dvokolwako Health Centre clusters) and the local filter clinics that feed into the primary 
“parent” care center. For the FAM-CARE study, the four clusters and the accompanying largest 
filter clinic for each cluster were randomized to initiate the FCCM program (Emkhuzweni and 
Pigg’s Peak clusters and their respective filter clinics Mangweni and Horo clinics) or to remain 
standard of care (Dvokolwako and Mbabane clusters and their respective filter clinics Balekane 
Nazarene and Lobamba clinics). Figure 1 shows the schema of study design for the evaluation of 
FCCM program (Appendix 1).
For the quantitative component, all children living with HIV under the age of 15 years receiving 
care at a study facility were eligible for enrollment in the prospective cohort regardless of 
treatment status if there was at least one other HIV-positive family member residing in the 
household receiving services at that facility. Children living with HIV were excluded from the study 
if they were attending care at a study facility only temporarily, they had no other HIV-positive 
family members in the household receiving services at the study facility, or the child or caregiver 
had a significant medical condition that would preclude active study participation. For the 
qualitative component, caregivers were eligible for IDIs if they were enrolled in the FCCM program 
at least 12 months prior to data collection and enrolled as a FAM-CARE study participant; HWs 
were eligible for IDI if they provided care in the FCCM site for at least 6 months prior to data 
collection.
Sample size
The sample size was powered to detect a difference in viral suppression (HIV RNA ≥1,000 copies/
mL) in children receiving ART in the FCCM sites to those receiving ART in control sites, with 80 
percent power at 5 percent significance levels to detect at least a 10 percent increase in viral 
suppression with FCCM, assuming a suppression rate of 80 percent in the control sites, or a 15 
percent increase in suppression if the control suppression rate was no more than 75 percent. 
Assuming 10 percent loss-to-follow-up, this required a sample of 444 HIV-positive children from 
unique families (222 from intervention sites and 222 from control sites). The study originally 
planned 18-month follow-up, but due to slower than expected enrollment, participants were 
followed up to 12 months, with exploratory analyses used for those children who had been 
followed up for 18 months to see if there were any differences in primary endpoints. 
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DESCRIPTION OF INTERVENTION
The FCCM is a differentiated service delivery (DSD) model aimed at providing more efficient 
and effective HIV services to promote better ART initiation and retention in families. At sites 
randomized to implement FCCM, HIV-positive children were provided HIV services along with at 
least one other family member (HIV-positive or HIV-negative) involved in the support of the child. 
A family member was defined as someone related to the child either by blood or adoption, or 
someone residing in the same household who was responsible for the child. Family members had 
to be willing to disclose their HIV status to other family members within FCCM, attend clinic visits 
with the child, and support the child during clinic visits and at home. Family members living with 
HIV were invited to receive HIV care and treatment services at the same facility with the child, 
and HIV-negative family members received non-communicable disease health care services. 
All family members living with HIV were to be seen together in the facility and receive their care 
together as a family unit, with chronic care files kept in one family folder. ART medications were 
to be prepared for the family in advance of their visit and families were to be prioritized to be 
seen (or seen on special clinic “family days”) to decrease waiting time. If all family members were 
stable, one family member could pick up medications for the entire family. Families in FCCM were 
seen at least once every quarter for family units with stable children as defined in the Eswatini 
Integrated HIV Management Guidelines 2018 for children. Families not meeting these criteria 
were seen monthly. For families with school-aged children, clinic visits were attempted to be 
scheduled around school holidays. Staff were trained in FCCM standard operating procedures 
(SOPs), which defined staff purpose, roles and responsibilities, and resources (Appendix 4 FCCM 
SOP and Appendix 5 Components of the FCCM Service Package). 
DATA COLLECTION METHODS
All data collectors were trained by EGPAF research staff. A five-day training was held for study 
nurses who were responsible for collecting data in interviews and chart reviews. Qualitative 
interviewers were trained in a separate five-day training that included qualitative data collection 
methods and the qualitative data collection tools. 
Following informed consent of the caregiver (and assent of children >12–14 years), data were 
collected through caregiver interviews and abstraction of facility, laboratory, and patient records 
using specific data collection forms. At enrollment, study nurses interviewed caregivers to collect 
demographic, medical, and HIV-related information about the caregiver, the child, and household 
members. Clinical laboratory data for caregivers, children, and other HIV-positive family members 
were abstracted from clinic medical records. Study nurses collected DBS specimens from children 
for viral load testing. Study follow-up visits were every three months for children and caregivers 
and were scheduled to coincide with routine clinic visits to the extent possible. At each study visit, 
study nurses obtained interim clinical history (e.g., medical/HIV history and CD4 count and, for 
children on treatment, ART history, current regimen, and adherence) through caregiver interview 
and medical chart abstraction. Data on clinic visit attendance and pharmacy drug pick-ups for 
children receiving ART were obtained by chart abstraction. DBS specimens were drawn from HIV-
positive children on ART for study viral load testing every six months. Data collection activities are 
presented in Appendix 2.
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For the qualitative component, semi-structured one-on-one IDIs were conducted with caregivers 
and HWs to assess feasibility and acceptability of the FCCM. All interviews were conducted in a 
private room at the health facilities in the preferred language of participants, SiSwati. Interviews 
took place during October to December 2018 in the four health facilities implementing the 
pilot FCCM program (Appendix 3); one to four caregiver interviews were conducted at each site. 
Eligible caregivers were selected from a list of caregivers enrolled in both the FCCM program 
and the FAM-CARE study using a computer-aided simple random method. The FAM-CARE 
study nurse contacted the selected caregiver to return on a scheduled day for the interview 
and communicated with research assistants when the caregiver was scheduled for the 
interview. Caregivers returning to the facility for the purpose of the interview received transport 
reimbursement. Topics covered during the interviews included experiences engaging in the FCCM 
program, views on the advantages and disadvantages of FCCM, and perceptions of differences 
in the provision of care through FCCM compared to the standard of care. For HW interviews, FAM-
CARE study nurses worked with the site nurse-in-charge to identify eligible HWs (providers of care 
in the FCCM program >6 months). If there were more HWs eligible than the range of IDIs selected 
for the facility, each HW was assigned a number and selected at random by lottery. The FAM-CARE 
study nurse contacted the selected HW and asked them to meet with the research assistant on 
a scheduled day for the interview. Interviews covered views on advantages and disadvantages of 
FCCM and barriers and facilitators in implementing the FCCM program. 
ETHICAL REVIEW
The FAM-CARE study was reviewed and approved by Population Council Institutional Review Board 
(IRB) and the National Health Research Review Board in Eswatini.
DATA ANALYSIS 
Demographic characteristics at enrollment were summarized using means (standard deviations) 
for continuous variables and proportions for categorical variables, stratified by FCCM intervention 
and control arms. Chi square tests of independence were used to identify any characteristics 
that differed significantly between the two study arms. The FCCM program decline rate was low 
(<10%) and enrollment characteristics of children in FCCM and control sites were similar, thus 
a simple chi-square test was used to compare the two proportions at 5 percent significance 
level. An intention-to-treat analysis was performed in which all children at facilities offering the 
FCCM program were compared to all children at facilities without the FCCM program. To identify 
factors associated with viral suppression and undetectability, unadjusted bivariate and adjusted 
multilevel logistic regression models were developed to estimate the association between viral 
suppression and undetectable viremia, and putative factors in each study arm. 
For the qualitative component, IDIs were audio recorded and transcribed in Microsoft Word, and 
simultaneously translated into English, by research assistants who conducted the interviews. 
The study team reviewed the transcripts and created a codebook based on the transcripts. 
Maxqda software was used to store and code transcripts. After coding was complete, data 
were summarized through descriptive, text-based summaries and tables by study investigators, 
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identifying themes and patterns in the data. Results are presented by group (caregivers and HW) 
and summarized into overall findings.
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KEY FINDINGS
QUANTITATIVE FINDINGS
A total of 379 HIV-positive children under the age of 15 years (207 in the intervention arm and 
172 in the control arm) from 363 unique families (203 in the intervention arm and 160 in the 
control arm) were enrolled in the study from September 2017 to July 2019. Table 1 shows the 
number of participants enrolled in the study by site and study arm. The unique families include 
363 caregivers (97% living with HIV) and 28 other family members living with HIV (children and 
adults) living in the same household as the child and caregiver. 
Table 1  Prospective cohort enrollment







Pigg's Peak Parent Intervention   61   62   3
Horo Filter clinic Intervention   40   41   7
Emkhuzweni Parent Intervention   58   59   8
Mangweni Filter clinic Intervention   44   45   1
Dvokolwako Parent Control   56   61   3
Bhalekane Filter clinic Control   39  41   2
Mbabane Parent Control   33   34   3
Lobamba Filter clinic Control   32   36   1
Total 363 379 28
Table 2 shows demographic characteristics of children at enrollment. Nearly half of all children 
(47%) were aged 5–9 years, one-third of children were aged 10–14 years and the rest were under 
the age of 5 years. Among children over age five years, 93 percent were in school. Of the children 
in school, 36 percent had missed school in the three months before enrollment; more children in 
the control than intervention group had missed school. 
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Less than a third of children (28%) had ever been hospitalized. Most of the 106 children who 
had ever been hospitalized (76%) had only been hospitalized once. Only six (6%) children had 
been hospitalized three to five times. Since initiating HIV care, almost all children (98%) had been 
continuously receiving care (Table 3, next page). 
At enrollment, 160 (42%) of all children knew their HIV status. Figure 1 (next page) breaks 
disclosure down by age group: 102/122 (84%) age 10–14 years knew their HIV status; 57/175 
(33%) age 5–9 years knew their HIV status; and almost all children under the age of 5 years were 
not aware of their HIV status. 












 Female 81 (47) 106 (51) 187 (49) 0.43
 Male 91 (53) 101 (49) 192 (51)
Age (years) 
Mean (SD) 8.1 (4) 8.6 (4) 8.4 (4) 0.20
0–<1 5 (3) 1 (.05) 6 (2)
1–<2 5 (3) 2 (1) 7 (2)
2–<5 27 (16) 35 (17) 62 (16)
5–<10 82 (48) 97 (47) 179 (47)
10–14 53 (31) 72 (35) 125 (33)
Child in school (n=133 control; n= 169 intervention)
Yes 125 (94) 155 (92) 280 (93) 0.45
No 8 (6) 14 (8) 22 (7)
Days missed school in past 3 months (n=125 control; n=155 intervention)
Did not miss 67 (54) 112 (72) 179 (64) 0.001
<7 days 58 (46) 39 (25) 97 (35)
7–14 days 0 (0) 3 (2) 3 (1)
15–30 days 0 (0) 1 (0.6) 1 (0.4)
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Figure 1  Children’s awareness of HIV status by age and group at enrollment












Yes    51 (30)   55 (27)   106 (28) 0.24
No 121 (70) 149 (72)   270 (71)
Other    0 (0)    3 (1)        3 (0.8)
Number of hospitalizations (n=46 control; n=50 intervention)
1    35 (76)   38 (76)     73 (76) 0.55
2      9 (20)     8 (16)      17 (18)
3–5    2 (4)   4 (8)     6 (6)
After entering HIV care, child continually in care 
Yes  171 (99) 202 (98)   373 (98) 0.33
No      1 (0.6)    4 (2)    5 (1)
Other    0 (0)       1 (0.5)        1 (0.3)
Child knows HIV status 
Yes    83 (48)    77 (37)   160 (42) 0.03
No    83 (48) 127 (61)   210 (55)
Other    6 (4)   3 (1)     9 (2)
Child currently on ART (n=206 intervention)
Yes   171 (99)     207 (100)      378 (99.7) NS
























All children were receiving ART at enrollment except one child. Figure 2 shows ART regimen 
type for children at enrollment. The majority of children were on zidovudine (AZT)+lamivudine 
(3TC)+nevirapine (NVP) (39%). Other regimens included, abacavir (ABC)+3TC+lopinavir/ritonavir 
(LPV/R) (19%), ABC+3TC+efavirenz (EFV) (17%), AZT+3TC+LPV/r (10%) and AZT+3TC+EFV (6%). 
In the year before enrollment, 30 percent of children had reported treatment interruptions.
Figure 2  Treatment regimen for children receiving ART at enrollment
At enrollment, 60 percent of children were adhering well (>95% doses) to their ART regimen, 
with only 6 percent with poor adherence (<85%) (Figure 3, next page). In the last 7 days before 
enrollment, 10 percent of children had missed their ART drugs at least once. A total of 85 percent 
of children had their last two ART refill pick-ups on time. 
At enrollment, 78 percent of children had achieved viral suppression (<1,000 copies/mL) (80% 
intervention and 77% control, p=0.68) and 74 percent of children had undetectable viremia 
(<400 copies/mL) (76% intervention and 72% control, p=0.51). Factors associated with viral 
suppression at enrollment were child’s age and ART regimen. Viral suppression was most likely 
among older versus younger children, with 82 percent in children aged 10–14 years; 80 percent 
in children aged 5–9 years; 74 percent in children aged 2–5 years; and 46 percent in children 
under age 2 years. Viral suppression was higher among those children on EFV-based regimen 
(87%) compared to NVP-based regimens (73%) and LPV/r-based regimens (79%). 
Of the 363 caregivers who enrolled in the study, 92 percent were women (Table 4, next page). 
Women caregivers were significantly younger than men caregivers (mean age (min, max): 35 
(15–73) versus 40 (27–67) years. About half of the caregivers were married or living together 
































Mean age child by regimen type
EFV regimen, mean age 10.3 yrs
NVP regimen, mean age 9.3 yrs
LVP/r regimen, mean age 5.5.yrs
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Median (range) 35 (15-70) 36 (21-73) 35.5 (15-73) NS
Gender
Female 147 (93) 186 (92) 333 (92) 0.77
Male 13 (8) 17 (8) 30 (8)
Education 
Never attended 20 (13) 31 (15) 51 (14) 0.22
Primary 67 (42) 68 (34) 135 (37)
Secondary 59 (37) 71 (35) 130 (36)
Beyond secondary 14 (9) 33 (16) 47 (13)
Marital status
Married 65 (41) 95 (47) 160 (44) 0.45
Living with partner 9 (6) 12 (6) 21 (6)
Single 60 (38) 59 (29) 119 (33)
Divorced/Widowed/Separated 26 (16) 37 (18) 63 (17)
 
Nearly all of the caregivers (97%) were living with HIV at enrollment (Table 5). About 41 percent of 
caregivers’ households had more than one adult living with HIV, and 10 percent had more than 
one child living with HIV in the household. 
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Positive 153 (96) 198 (98) 351 (97) 0.31
Negative 7 (4) 5 (3) 12 (3)
Number of HIV+ adults in caregiver household including caregiver
 0 4 (3) 2 (1) 6 (2) 0.55
 1 87 (54) 122 (60) 209 (58)
 2+ 69 (43) 79 (39) 148 (41)
Number of HIV+ children in caregiver household
 1 143 (89) 184 (91) 327 (90) 0.56
 2 13 (8) 16 (8) 29 (8)
 3–4 4 (3) 3 (2) 7 (2)
Number of HIV+ members on ART in caregiver household including caregiver and child
 1 88 (55) 121 (60) 209 (57) 0.74
 2 61 (38) 71 (35) 132 (36)
 3+ 11 (7) 11 (5) 22 (6)
 
All caregivers living with HIV were receiving ART at enrollment (Figure 4). At enrollment, 62 
percent of caregivers were receiving tenofovir disoproxil fumarate (TDF)+3TC+EFV, 21 percent 
were on AZT+3TC+NVP, and the rest were on other regimens. Most caregivers receiving ART were 
on EFV-based regimens, 25 percent were on NVP-based regimens, and 4 percent were on LPV/R-
based regimens with NRTI backbones of ABC, AZT, or TDF plus 3TC. 
Figure 4  ART regimen of caregivers at enrollment
AZT+3TC+NVP AZT+3TC+EFV
n=7
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Viral suppression among HIV-positive children during study
The total number of children with viral load test results decreased over time from 375 (100%), 
337 (90%), 346 (84%), and 216 (58%) at enrollment, 6, 12, and 18 months, respectively, with 
no significant difference between study groups. There was no statistically significant difference 
in viral suppression or detectability by study arm at 12 or 18 months. Overall, viral suppression 
improved between enrollment and 12 months follow up in both arms, from 78 percent at 
enrollment (80% intervention, 77% control) to 90 percent at 12 months (89% intervention, 92% 
control); and was 87 percent at 18 months (91% intervention, 83% control). The overall proportion 
of children who achieved undetectable viral load increased from 74 percent at enrollment (76% 
intervention, 72% control) to 87 percent at 12 months (88% intervention, 86% control) and 84 
percent at 18 months (86% intervention, 82% control). 











Viral suppression at enrollment
HIV RNA <1,000 copies/ mL 130 (77) 164 (80) 294 (78) 0.41
HIV RNA ≥1,000 copies/mL 40 (24) 41 (20) 81 (22)
Viral suppression at 12-month follow-up
HIV RNA <1,000 copies/ mL 120 (92) 165 (89) 285 (90) 0.48
HIV RNA ≥1,000 copies/mL 11 (8) 20 (11) 31 (10)
Viral suppression at 18-month follow-up
HIV RNA <1,000 copies/ mL 88 (83) 100 (91) 188 (87) 0.08
HIV RNA ≥1,000 copies/mL 18 (17) 10 (9) 28 (13)
Undetectable viremia at enrollment
HIV RNA <400 copies/ mL 122 (72) 155 (76) 277 (74) 0.40
HIV RNA ≥400 copies/ mL 48 (28) 50 (24) 98 (26)
Undetectable viremia at 12-month follow-
up
HIV RNA <400 copies/ mL 113 (86) 163 (88) 276 (87) 0.63
HIV RNA ≥400 copies/ mL 18 (14) 22 (12) 40 (13)
Undetectable viremia at 18-month follow-
up
 
HIV RNA<400 copies/ mL 87 (82) 94 (86) 181 (84) 0.50
HIV RNA ≥400 copies/ mL 19 (18) 16 (15) 35 (16)
 
Among the 252 children who had viral suppression at enrollment, 97 percent remained 
suppressed at 12 months follow up (98% intervention, 95% control, p=0.23); and 62 percent of 
children who were unsuppressed at enrollment achieved viral suppression at 12 months follow 
up (54% intervention, 75% control, p=0.10); there were no significant differences between study 
groups (Table 7).
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Table 7  Viral suppression in children at 12- and 18-month follow-up by viral suppression status 








Among children suppressed at enrollment, viral suppression at 6-month follow-up
HIV RNA <1,000 copies/mL                              108/113 (96%) 143/150 (95%) 251/263 (95%)
Among children not suppressed at enrollment, viral suppression at 6-month follow-up
HIV RNA <1,000 copies/mL                                                    14/31 (45%) 14/40 (35%) 28/71 (39%)
Among children suppressed at enrollment, viral suppression at 12-month follow-up   
HIV RNA <1,000 copies/ mL 101/106 (95%) 143/146 (98%) 244/252 (97%)
Among children not suppressed at enrollment, viral suppression at 12-month follow-up
HIV RNA <1,000 copies/mL 18/24 (75%) 20/37 (54%) 38/61 (62%)
Factors associated with viral suppression and undetectable viremia
In unadjusted bivariate analyses among all children at 12 months after enrollment, several 
factors were significantly associated with viral suppression (HIV RNA <1,000 copies/mL). Children 
who were not aware of their HIV status tended to be less likely than children who were aware 
of their HIV status to be virally suppressed (OR:0.46; 95% CI: 020, 1.08). Compared to children 
with caregivers under age 25 years, children with older caregivers aged 30–40 years (OR: 5.53; 
95% CI: 1.80, 17.00) and aged >40 years (OR: 3.93; 95% CI: 1.30, 11.85) were significantly more 
likely to be suppressed. Most caregivers were living with HIV, with only 12 caregivers being HIV-
negative. The odds of suppression among children with HIV-negative caregivers were significantly 
lower than the odds of suppression among children with HIV-positive caregivers (OR: 0.15; 95% 
CI: 0.05, 0.49). At study entry, children on NVP-based ART had significantly lower levels of viral 
suppression (73%) than those on EFV-based (87%) or LPV/r-based ART (79%) (p=0.04). While 
rates of viral suppression at 12 months after enrollment remained lowest in those on NVP-
based ART (87%) compared to EFV-based ART (94%) and LPV/r-based (91%) ART, this was not 
statistically significant (p=0.31). Study intervention versus control group was not statistically 
significantly associated with viral suppression at 12 months (p=0.48) or 18 months (p=0.08) 
after enrollment.
In unadjusted bivariate analyses among all children at 12 months, similar factors were associated 
with undetectable viremia (HIV RNA <400 copies/mL). The odds of undetectable viremia tended 
to be lower among children who did not know their HIV status compared to children who did know 
their HIV status (OR: 0.55; 95% CI: 0.26, 1.14, p=0.10). Children in the care of older caregivers 
aged 30–40 years (OR: 5.24; 95% CI: 1.83, 15.04) and older than 40 years (OR:3.15; 95% 
CI:1.14, 8.68) were more likely to have undetectable viremia than children in the care of younger 
aged caregivers aged under 25 years. Children in the care of HIV-negative caregivers versus HIV-
positive caregivers were less likely to have undetectable viremia (OR:0.15; 95% CI: 0.05, 0.46). 
The odds of undetectable viremia were significantly lower among children in households with 
three or more HIV-positive children versus children in households with two or fewer HIV-positive 
children (OR: 0.21; 95% CI: 0.06, 0.78). Although undetectable viremia at 12 months after 
enrollment was lowest among children on NVP-based ART (84%) compared to EFV-based (90%) 
and LPV/r-based (89%) ART, this was not statistically significant (p=0.38). Study intervention 
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versus control group was not statistically significantly associated with undetectable viremia at 12 
months (p=0.63) or at 18 months follow (p=0.38). 
There was an association of age with suppression and undetectable viral load. Overall, 93 percent 
of children aged 10–14 years had viral suppression at 12 months follow up compared with 88 
percent of children aged 5–9 years and 76 percent of children aged under 5 years. Similarly, 
undetectable viral load was observed in 91 percent of children aged 10–14 years, 87 percent of 
those aged 5–9 years, and 81 percent of those aged under 5 years. There was not a significant 
difference in the levels of suppression or detectability by intervention versus control group when 
stratified by age. 
Retention in care, adherence, interruptions in ART care, and HIV 
disclosure 
There were no significant differences between intervention and control groups in retention in care, 
interruption of ART, or reported adherence or disclosure at 12 months (Table 8). At 12 months 
of follow-up, 93 percent of children expected to be seen at the 12-month visit had a documented 
clinic visit, with no significant difference between groups (91% intervention, 94% control, 
p=0.53). At the 12-month visit, ART interruption was reported by 16 percent in the intervention 
and 15 percent in the control groups (p=0.82); good adherence was reported by 84 percent in 
the intervention and 87 percent of the control groups (p=0.32); and last two drug pick-ups were 
reported to be on time for 88 percent of intervention and 92 percent of control group children 
(p=0.18). The proportion of children who did not know their HIV status at enrollment but learned 
their HIV status during the study was low and not statistically different between groups (6% 
intervention and 5% control. p=0.69). In the more limited sample of 216 children with 18-month 
follow-up, 12 percent reported ART interruption, 93 percent reported good ART adherence, and 
87 percent reported last two drug pick-ups were on time, with no significant differences between 
groups.









Number with clinic visit/number 
expected for visit 
152/161 (94) 178/195 (91) 330/356 (93) 0.31
12-month visit ART adherence*
ART interruption since last visit 19/131 (15) 26/168 (16) 45/299 (15) 0.82
Good reported adherence 95/109 (87) 102/121 (84) 197/230 (86) 0.32
Last 2 drug pick-ups on time 134/145 (92) 153/174 (88) 287/319 (90) 0.18
New disclosure during study**
New HIV disclosure to children who 
did not know status at enrollment
4/79 (5) 8/125 (6) 12/204 (6) 0.69
*Data missing for ART interruption for 55/354 (16%) children (30/161 control, 19%; 25/193 intervention, 13%); ART adherence 
124/354 (35%) children (52/161 control, 32%; 72/193 intervention, 37%); and drug pick up for 35/319 (11%) children 
(16/161 control, 6%; 19/193 intervention, 10%)
**Data on child disclosure status at enrollment were available for 370/379 (98%) children, with 210 undisclosed; data on 
subsequent disclosure were available for 204/210 (97%) (79/83 control, 95%, and 125/127 intervention, 98%) 
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QUALITATIVE FINDINGS
In this section of the report, key findings from semi-structured interviews with caregivers and 
health workers engaged in the FCCM program are presented. Key themes are described in the 
following order: demographic characteristics of caregivers and HWs, benefits of FCCM, challenges 
in participating in FCCM and in implementation, and recommendations for improving the FCCM 
model in the Eswatini context. 
Characteristics of semi-structured interview participants
Semi-structured interviews were conducted 
with 25 caregivers participating in the FCCM 
program in four intervention sites. Table 9 
presents caregiver demographic data. Of 
the 25 caregivers, only two were men, most 
were married or cohabitating (17 of 25), 
and the mean age was 37.8 years. The child 
and caregiver were the only family members 
enrolled in the FCCM program in 19 of the 25 
caregiver households, and 16 caregivers were 
the biological parent of the child. All of the 
caregivers and their children were HIV-positive 
and on ART at the time they were interviewed for 
the study.










Primary and lower 12 (48)
Beyond primary 13 (52)
Marital status
Never married 8 (32)
Married, non-polygamous 10 (40)






Biological parent 16 (64)
Number of HIV-positive family 
members enrolled in FCCM
2 (caregiver and child) 19 (76)
3+ 6 (24)
Child currently on ART 25 (100)
Caregiver currently on ART 25 (100)
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A total of 17 health workers were interviewed for the 
FAM-CARE study; their demographic data are shown 
in Table 10. Most of the HWs were women (14 of 17) 
and had some secondary education (12 of 17). Most 
common roles of the HWs interviewed were midwife 
or expert client. 
Benefits of FCCM
Caregivers said that they felt that FCCM 
strengthened the family bond. FCCM was perceived 
as encouraging family members to disclose their 
HIV status to other family members, including to 
male partners and the child. Caregivers said they 
felt this helped to reduce stigma within the family 
by encouraging family members to talk more openly 
about living with HIV and taking ARV drugs. If one 
family member forgets to take their medication, 
another family member can remind them. Caregivers 
also viewed their disclosure with their children 
as a positive way for the child to see that the caregiver is also living with HIV and taking their 
medication, motivating the child to continue to participate in FCCM and take their medication. 
Caregivers said that for some men, participating in FCCM helped them in their caregiver role and 
to support women and children in the family in HIV care and treatment. 
“
Another thing is that there is no more hiding from each other to take pills on time. 
Even my child is always reminding us that it is now time to take pills so we do things 
together. No one to say, eish…now it is time for medication, the child also knows the dates. 
Even in January the child will come again for the next visit. The family is always free to do 
things together. It is like a game to us now because we are happy.
—Female caregiver, age 29, of boy age 8 
Caregivers also viewed FCCM as having practical benefits in saving time. Caregivers liked the “fast 
tracking” where, as participants in FCCM they were moved to the front of the line. This reduced 
time at the facility typically spent waiting in line. 
“
… I am now more comfortable unlike before when I would think of going to the 
facility, I would first think of the long lines and would be irritated in one way or the 
other. The FCCM patients are the ones provided with services first, and they always tell us 
to come early in the morning as we are the first clients to be taken care of.
—Female caregiver, age 43, of boy age 13
Caregivers’ perceived the FCCM program to offer better counseling than the counseling 
provided in the standard of care, and that HWs in FCCM were taking “good care” of them. 
Patient files in FCCM were viewed by caregivers as being kept more confidentially than in the 
standard of care. Caregivers liked that FCCM provided call reminders for upcoming visits and 
the fact that they saw the same HW at each clinic visit. 









High school 1 (6)
Tertiary 14 (82)
Current role in health facility
Midwife 6 (35)
Expert client 6 (35)
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“
When I used to come before I was enrolled in FCCM they would just count my pills, 
but now when I come I would always talk to a nurse in a certain room [who would] 
ask me how do I feel, how is the child doing on his treatment. Then that would make me 
feel happier to get such a warm welcome from a health care worker.
—Female caregiver, age 28, of girl age 7
“
And what I like with FCCM program is that, if there is one member who doesn’t drink 
the medication or doesn’t adhere, the HW are able to correct our mistakes, motivate 
us and encourage us together as a family.
—Male caregiver, age 40, of girl age 13 
HWs said the FCCM program enabled them to gather and track family histories, identify fam-
ily challenges to HIV care and treatment, and identify long-lasting solutions. HWs said FCCM 
facilitated communication among family members, encouraging individuals to share more of 
their needs together with other family members. Meeting with caregivers and their children 
together provided an opportunity for HWs to assist caregivers in disclosing their HIV status 
to the child. HWs liked having patient files for each family pulled ahead of time and grouped 
together for the clinic visit. 
“
Addressing them as a family is much better because everyone will say their side they 
want to talk about, they don’t talk about each other. When they are together there 
will be some transparency. They will be able to talk to each other. It has also helped us with 
disclosure, even if the mother was scared to tell the child, they can now tell the child as a 
family.
—Female health care worker, age 37
HWs said FCCM improved the patient-provider communication and relationship, where pa-
tients could ask questions of providers and were more actively seeking information during 
clinic visits.
Challenges in FCCM
Caregivers had to incur additional costs for clinic visits for multiple family members, as FCCM 
required the family to visit the clinic together. There were schedule conflicts with clinic visits for 
school-aged children attending school and weekend teen support groups. It was also difficult for 
some caregivers to encourage men in their families to participate in FCCM because men did not 
want to get an HIV test. Caregivers also said that sometimes in the facility when they could step to 
the front of the line as part of the “fast tracking” of FCCM participants, other clients in the waiting 
room criticized them and complained. 
At some facilities, HWs said that some families did not attend clinic visits together as a family 
unit. Some families rotated family members to come pick up medication for the whole family. HWs 
also noted that some families were food insecure and children would skip taking their medication 
because taking it on an empty stomach made them feel sick. 
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HWs also had challenges with managing larger groups of family members at the same time and 
experienced staff shortages. HWs said sometimes family members did not get along and this 
was difficult to manage. When there were larger groups and staff members were seeing multiple 
clients at one time, the clinic visits took longer, and some facilities did not have enough staff to 
cover the visits.
While caregivers said FCCM encouraged disclosure, many HWs saw disclosure as a challenge of 
implementing FCCM. Disclosure in the context of the family was difficult for many family members 
because of the fear of what other family members or partners would think of them and fear of 
family members gossiping about them to others. Many children were not aware of their HIV status 
because caregivers were unable to fully disclose the child’s status. 
“
As the disclosure has been a problem, parents were anxious on how they will tell 
their children… they cannot disclose well.
—Female health care worker, age 54
“
But then the challenge that I have is that my son keeps asking me when will he stop 
taking the pills? He always says that he is tired of taking the pills, the child further 
says that he is not sick, he feels better now. 
—Female caregiver, age 28, of boy age 10
In particular, both HWs and caregivers said that encouraging men to participate in FCCM was a 
challenge. Some men were hesitant to receive HIV testing and counseling as part of the FCCM 
program. Both caregivers and health workers mentioned difficulty in discussing sensitive health 
information in the presence of other family members. For HWs, it was a challenge to ask sensitive 
questions, such as asking adolescents about their sexual activity in the presence of their 
caregiver or asking caregivers about reproductive health and family planning use in front of their 
children. 
Recommendations for FCCM strengthening and scale-up
Most participants felt that the FCCM program should be continued and scaled-up nationally. The 
FCCM program was well-liked by participants, who thought the program should continue and 
should be expanded to other communities. Scale-up was recommended by participants because 
they perceived the program provided benefit in reducing stigma within the family and promoted 
more open discussion about HIV and HIV disclosure within the family. Participants said that the 
encouragement to disclose helped family members support one another in adherence to ART and 
clinic appointments. For some families, FCCM saved money in transport costs in attending clinic 
visits.
HWs stated they would like more training on how to ask sensitive questions within the context of 
a family clinic visit and how to offer counseling to caregivers to disclose their HIV status to family 
members and to children, and to disclose the child’s HIV status to the child. HWs also wanted 
more training in how to manage family dynamics and what to do if family members do not get 
along. 
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HWs suggested adding a social worker to the FCCM provider team to address psychosocial needs 
of families in HIV care and treatment. The FCCM does not currently include a social worker. To 
address the additional work burden and extended time of the clinic visit for HWs to see multiple 
family members in one visit, HWs suggested increasing the number of staff at the facility on 
FCCM clinic days. 
Caregivers and HWs suggested designating specific days for FCCM clients only, to reduce the 
amount of time FCCM clients wait in line if they are not “fast tracked” to the front. Both caregivers 
and HWs also suggested preparing the families’ medications ahead of the clinic visit so family 
members do not have to wait in long pharmacy lines to receive their medication. 
Another suggestion was to offer other types of care such as screening tests for blood sugar levels 
or taking care of other health concerns such as head or stomach pain, during the FCCM clinic 
visit. Seeing the same nurse at each visit and adding more FCCM staff with specific roles and 
responsibilities were suggested by both caregivers and HWs for improving service delivery. HWs 
reported an increased work burden to provide care to families rather than to individual clients 
during clinic visits. The FCCM clinic visits take longer and some HWs said their facility did not 
have sufficient staff to cover these longer visits and attend other clients; thus, adding staff for 
FCCM programming would improve wait times during the FCCM clinic visits.
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DISCUSSION 
The study arm was not significantly associated with viral suppression or undetectable viremia at 
12 (or 18) months after enrollment. Participation in FCCM did not show any statistically significant 
improvements in retention, adherence, ARV drug refill pick-ups, or children who knew their HIV 
status versus control groups. In the control arm, high proportions of children had achieved viral 
suppression, retention, and adherence. In order to detect a difference in these outcomes, a 
significantly larger sample size would have been required.
Analysis of enrollment data demonstrated that factors associated with lack of viral suppression 
included younger age (<5 years) and treatment regimen, with children receiving NVP-based ART 
significantly less likely to have viral suppression. When children are on a suboptimal regimen, they 
are less likely to achieve viral suppression. These results highlight the importance of programs 
in Eswatini and elsewhere to monitor treatment regimens as children age and ensure WHO 
guidelines for treatment regimens are implemented to optimize pediatric outcomes. Following 
mid-study analysis of enrollment data demonstrating that a significant proportion of children 
were receiving suboptimal ART, EGPAF developed a briefing sent to all EGPAF countries regarding 
the need to review and optimize ART regimens in all children (Appendix 6). These data were also 
published in Pediatric Infectious Disease Journal to get wider dissemination of the critical need 
to continually review ART regimens to ensure optimization of ART in children as they age up 
(Chouraya et al. 2019)
Caregivers and HWs involved in FCCM discussed both benefits and challenges of FCCM in 
qualitative interviews. Caregivers perceived improved adherence, retention in care, and overall 
health of children in the program. HWs said FCCM encouraged HIV disclosure and support for 
adherence among family members. However, HWs said that timing of teen support groups and 
school schedules were not coordinated well with clinic visits. There was a lack of fidelity to the 
FCCM model noted, with some sites reporting that families did not attend clinic visits together as 
a family, but rotated family members to come get medication for the whole family. Both caregivers 
and HWs had difficulties in discussing sensitive health information in the presence of other family 
members. According to FCCM program data, only 40 percent of all 465 families enrolled in the 
program at the pilot sites actually attended at least one clinic visit together as a family, and only 
26 percent of families attended clinic visits together four times a year. Attendance at FCCM was 
not related to age of the child; similar proportions of families with a child under 10 years of age 
(42%) versus with a child at least 10 years of age (38%) attended at least one clinic visit together 
as a family. Families enrolled in FCCM with only two members living with HIV (e.g., caregiver and 
child) were more likely to have attended at least one clinic visit as family than those with more 
than two family members living with HIV (47% versus 20%, respectively). 
Results from the quantitative data reflect the challenges discussed in qualitative interviews. One 
of the challenges of participating in FCCM was schedule conflicts with school and teen support 
groups. Because of these challenges, caregivers with older children may have been less likely to 
attend clinic visits with their child than caregivers with younger children. Both HWs and caregivers 
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said they had difficulty discussing sensitive health information in the presence of other family 
members. For older children and their caregivers, these factors may have been more of a barrier 
to attend clinic visits together than caregivers with younger children. However, children aged at 
least 10 years had the highest rates of viral suppression compared to younger children; 12-month 
suppression was 94 percent and undetectable viral load was 91 percent. Understanding the 
role of teen support groups in improving viral suppression and adherence among adolescents 
compared to FCCM or similar family-centered care models would be helpful. While this suggested 
to us that perhaps FCCM may be most effective among the younger children, when doing a 
stratified analysis by age under 5 years, 5–9 years and more than 10 years, there did not 
appear to be a differential effect of FCCM on viral suppression by age, with suppression and 
undetectability not significantly different between FCCM and control children, regardless of age. 
Children who did not know their HIV status tended to be in the care of younger caregivers and 
have HIV-negative caregivers and were less likely to achieve viral suppression at 12 months 
after enrollment. Supplemental training for health providers engaged in FCCM in how to support 
caregivers in disclosing the child’s HIV status could improve the proportion of children who know 
their HIV status, a need specifically noted by HWs in the qualitative component of the study. 
Adolescent or young adult caregivers may need additional support in caring for children living 
with HIV, including administration of the recommended ART regimens, adhering to clinic visit 
schedules, and HIV disclosure to the child. Providers may need additional training in counseling 
and identifying the needs of younger caregivers to be able to effectively support and counsel 
them. The complex psychosocial needs identified by HWs who participated in semi-structured 
interviews and their recommendation to have social workers added to the care team reflects an 
important gap in adequately addressing structural and social barriers within the family that can 
affect HIV outcomes for children. 
PEPFAR guidance stipulates that “differentiated care and innovative service delivery (DSD) 
models should focus on populations that have difficulty with retention, such as children, 
adolescents, young adults, men, pregnant women, and key populations. Adherence programs 
should be focused on the clients with elevated viral loads and not generic programs to all clients.” 
The FCCM program is considered a DSD service delivery model for children and families. One 
of the lessons learned through implementing the FCCM is that children older than 10 years 
prefer peer to peer support through the teen support groups rather than being accompanied 
by caregivers to clinic appointments. The model is also helpful for those on treatment failure 
(caregivers and children) to better monitor and counsel caregivers and children in adherence. 
Drug dispensing should be aligned to the extent possible for stable caregivers and children so 
that they are able to attend FCCM visits on the same schedule. These lessons learned align with 
PEPFAR guidance on DSD and multi-month dispensing of medication.
LIMITATIONS
There are several limitations to the study. Given slower than expected enrollment, the overall 
sample size was lower than planned (379 versus 444). Slow enrollment resulted in reducing 
the follow-up time from 18 to 12 months in order to adhere to the study timeline, with only 57 
percent of children followed for the full planned 18 months, limiting the power of the study to 
detect differences between study arms for children over time. Additionally, given the high levels 
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of viral suppression, retention, and adherence at baseline in both FCCM and control children, it 
would have required a significantly larger sample size to be able to detect a difference in these 
outcomes with the FCCM program. 




Children had high levels of viral suppression and undetectable viremia at enrollment, which 
further improved by 12 months after enrollment, with no significant differences between FCCM 
intervention and control groups. Factors associated with viral suppression at 12 months after 
study entry included child’s awareness of their HIV status, caregiver’s age, and caregiver’s HIV 
status, with similar factors associated with undetectable viremia. 
Enrollment data demonstrating that a significant proportion of children were receiving suboptimal 
NVP-based ART, which was associated with lower levels of viral suppression, were important to 
direct attention to the critical need to review and optimize ART regimens in all children as they 
age up and more potent and less toxic regimens may become available. 
Overall, caregivers and health workers who participated in semi-structured interviews liked the 
FCCM program and valued the services received through the program. Caregivers felt FCCM 
promoted disclosure to other family members, reducing HIV stigma and encouraging adherence 
support for each other. Caregivers perceived FCCM as improving both ART adherence and 
retention in care, as well as the overall health of the child. HWs viewed FCCM as improving 
patient-provider communication and facilitating tracking patient histories. Challenges were also 
discussed. Caregivers reported scheduling conflicts with school schedules and teen support 
group meetings. HWs noted poor fidelity to the FCCM intervention, with some families not 
attending clinic visits together as a family as a whole, but rather rotating family members to 
come to the facility to pick up medication for all family members. Both caregivers and HWs had 
difficulties with sharing sensitive health information in the presence of other family members. 
Given the favorable view by caregivers and HWs, the government of Eswatini plans to implement 
the FCCM as one of the DSD models for HIV care for families. These findings highlight important 
considerations for improving pediatric HIV care as well as FCCM programs for younger-aged 
caregivers and HIV-negative caregivers, and for HWs in supporting caregivers in disclosing HIV 
status to children. Given the high rates of suppression in older children, evaluation of the effects 
of teen support clubs on HIV pediatric outcomes could illuminate how sufficient teen support 
groups are in ensuring ART adherence and viral suppression among older children. Based on 
these findings, specific recommendations are provided here for consideration in planning for 
national scale up of FCCM in Eswatini. These findings and recommendations may apply to similar 
country contexts in sub-Saharan Africa.
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RECOMMENDATIONS
As the Eswatini Ministry of Health plans for FCCM program scale up, several important 
recommendations based on these study findings could improve program implementation and 
thus achieve better pediatric HIV outcomes. These recommendations would be able to improve 
implementation of the FCCM program and are also relevant to pediatric HIV care in general:
 y Continue to ensure access to treatment regimen and viral load monitoring in order to optimize 
pediatric treatment regimens.
 y Provide additional training to health providers in counseling and support to caregivers for HIV 
disclosure to the child and to other family members.
 y Provide additional counseling and support for younger caregivers (<25 years of age) with 
children in HIV care and treatment.
 y Provide additional support to caregivers who have younger children in HIV care and treatment, 
where rates of viral suppression are lower.
 y Revise the FCCM SOPs and programming to aid implementation with fidelity:
  Improve coordination of the timing of FCCM clinic visits for school-aged children to better 
accommodate school and teen support group schedules. 
 ○ FCCM is most appropriate for children younger than age 10 years and their caregivers, and 
for caregivers and children experiencing treatment failure. Children 10 years and older 
benefit more from peer to peer support through the teen support clubs.
 ○ Disclosure is only assessed once during the clinic visits, at enrollment. Disclosure should 
be assessed at different time points along the cascade as the child’s understanding of their 
HIV diagnosis changes over time.
 ○ At enrollment see all family members, conduct baseline assessment to ascertain if families 
need frequent monitoring or less. 
 ○ For stable families, visits can be scheduled quarterly aligning with school holidays. 
 ○ Align caregiver and child’s schedule for drug dispensing for stable patients, and advocate 
and mentor health care workers to offer multiple month refills for children. 
 ○ Ensure the number of families with appointments are manageable in a day. Family 
appointments should be distributed across several days as opposed to all families visiting 
health facilities on a single day. Appointments should be based on family sizes. 
  Include additional training for health providers in counseling and talking to adults about 
sensitive health topics in the context of the family and in managing larger groups during clinic 
visits.
  Add social workers to the FCCM care team to address psychosocial needs of program 
participants.
•	Evaluate the effects of teen support groups on ART adherence and viral suppression in older 
children.
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APPENDICES
APPENDIX 1  
SCHEMA OF STUDY DESIGN FOR THE EVALUATION OF  
FAM-CARE PROGRAM DESIGN
Four clusters of health care facilities/clinics in Hhoho Region Eswatini
Two hospital-based clusters with their filter clinics and two health cetner-based 
clusters with their filter clinics
Random selection of clusters (stratified by whether health center vs hospital 
cluster) to implement family-centered model or continue standard of care
Randomized cluster selection  
for implementation
FAMILY-CENTERED CARE MODEL IMPLEMENTATION
Emkhuzweni Health Center cluster
Three filter clinics
Pigg’s Peak Hospital cluster
Ten filter clinics
CONTROL STANDARD OF CARE CONTINUED








Pigg’s Peak Hospital cluster
Horo Clinic
Study Arm 1 Cohort Enrollment
(Control Standard of Care)
Dvokolwako Health Center cluster
Balekane Nazarene Clinic 
Mbabane Hospital cluster
Lobamba ART Clinic
Enroll HIV-positive child <15 years
• Receiving ART (endpoints: viral load 
suppression/HIV RNA >1,000 c/mL; pattern of 
retention)
• Not receiving ART (endpoints: ART initiation; 
viral suppression/HIV RNA >1,000 c/mL; 
pattern of retention)
Follow-up: 12 months (originally 18 months)
Enroll HIV-positive child <15 years
• Receiving ART (endpoints: viral load 
suppression/HIV RNA >1,000 c/mL; pattern of 
retention)
• Not receiving ART (endpoints: ART initiation; 
viral suppression/HIV RNA >1,000 c/mL; 
pattern of retention)
Follow-up: 12 months (originally 18 months)
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APPENDIX 2  
DATA COLLECTION ACTIVITIES 
Data collection Enrollment Months
3 6 9 12 15 18
All children living with HIV
Demographic data X
HIV and ART history X
Current ART regimen (regimen, 
adherence, drug pick-up) 
X X X X X X X
Interim (between visits) HIV history X X X X X X
CD4 count (medical chart abstraction) X X X X X X X
Medical visit attendance timeliness/
missed visits
X X X X X X
Viral load test (drawn for study) X X X X
Caregivers and other family members 
living with HIV
Demographic data X X
Family HIV history X
HIV+ caregiver ART and viral load 
history (interview and medical chart 
abstraction)
X X X X X X X
HIV+ family member ART and viral 
load history (interview and medical 
chart abstraction)
X X X X
*Collected any time a child was initiated on ART (on ART at entry or starts ART during study)
APPENDIX 3 
IDIS CONDUCTED IN EACH FAM-CARE PROGRAM SITE
Facility name Facility type Facility 
ownership
Number of caregivers 
interviewed
Number of HWs 
interviewed
Pigg’s Peak Government Hospital Public 9 7
Horo Clinic Public 5 3
Emkhuzweni Health center Public 7 5
Mangweni Clinic Public 4 2
Total 25 17
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APPENDIX 4 
FIVE STEPS IN PROVIDING FCCM FROM FCCM STANDARD 
OPERATING PROCEDURES (SOP)
1. Sensitization of clients about FCCM
The expert clients, HTS counselors, and nurses included FCCM during the health talks in the 
morning and during one-on-one counseling using FCCM sensitization script.
2. Enrollment into FCCM
Expert clients identified eligible index children already receiving HIV care or treatment 
services and invited eligible family members for enrollment into the FCCM directly by using 
the FCCM invitation letter or through a phone call. The family unit folder was created, the 
program enrollment form completed, and all individual chronic care files retrieved for all family 
members and put into the family folder. Each family folder was given an FCCM number that 
was also documented on the patient booklet. Invitations for index testing were provided by the 
HTS counselors on their return.
3. Organization of family folders and scheduling family appointments
Nurses scheduled follow up appointments for all individuals in the family unit enrolled in 
FCCM on the same day and completed documentation in the chronic care file and patient 
booklet. The expert client completed documentation of the family appointment date into the 
appointment register, and the expert client or data clerk refiled the family folder according to 
the family unit number in the designated filing cabinet. Appointment reminders were sent to 
the family 3 days before their appointment visit.
4. Family follow up visits before arrival at the facility
The expert clients and data clerks retrieved all family folders for families scheduled for a 
particular day and the nurse reviewed the individual chronic care files to request or follow up 
particular lab tests, results, or other care as needed. Medications were prepared for family 
units at two clinics (Horo and Mangweni). However, at Emkhuzweni Health Centre and Pigg’s 
Peak Hospital, pending authorization for drug distribution in the hospitals and health centers, 
prescriptions were written and dispensed on the day of the visit.
5. Family follow up visits on arrival at the facility
Family units were “fast tracked” to the expert client on arrival, circumventing some of the lines 
for receiving care, and documentation was updated in the appointment register.
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APPENDIX 5 
FAM-CARE PACKAGE OF SERVICES 
ART clinic
Multi-disciplinary team: AIDSFree mentors, facility doctors, nurses, expert clients, social workers, 




1. Family-centered assessment of adherence
2. Family-centered adherence support 
3. Family counseling and assisted disclosure support
4. Patient education in the context of the family to increase patient adherence, treatment, and 
viral load literacy in preparation for long term adherence +/- a change in ART regimen. 
5. Medical history and examination
6. Screening and treating comorbidities/opportunistic infections 
7. Refill ARVs and prophylactic medications (CTX, IPT, Fluconazole) and adjust ART doses and 
schedule (same appointments for all individuals in the family unit enrolled in FAM-CARE)
8. Laboratory monitoring 
9. Index testing for family members for ART initiation
10. Referrals for other services (social worker support, nutritional support, cervical cancer 
screening, family planning, etc.)
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APPENDIX 6  
EGPAF EVIDENCE TO ACTION: URGENT UPDATE! OPTIMIZING 
PEDIATRIC REGIMENS BRIEF
Available on next page and available for download here: https://www.pedaids.org/resource/
optimizing-pediatric-regimens/.
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APPENDIX 7 
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